Viemed Healthcare Announces Strong First Quarter 2026 Financial Results

Lafayette, LA, May 5, 2026 – Viemed Healthcare, Inc. (NASDAQ: VMD), a national leader in respiratory care and home medical equipment, has released its financial results for the first quarter ended March 31, 2026. The Company also provided updates on its financial position, share repurchase activity, and issued guidance for 2026.

Key Financial Highlights

• Net Revenue: Viemed reported net revenue of \$50.3 million for Q1 2026, marking a year-over-year increase from \$44.0 million in Q1 2025, representing a growth rate of approximately 14.3%.
• Adjusted EBITDA: The company posted Adjusted EBITDA of \$14.3 million for the quarter, up from \$13.0 million in the prior year period, showing continued operational strength and margin improvement.
• Net Income: Net income attributable to Viemed was \$2.7 million, relatively flat compared to \$2.7 million in Q1 2025, indicating stable profitability despite increased operating expenses and investments in growth.
• Free Cash Flow: Free cash flow for the quarter was \$2.6 million, and \$36.3 million for the trailing twelve months, highlighting Viemed’s robust cash generation.
• Balance Sheet: As of March 31, 2026, Viemed reported total shareholders’ equity of \$145.8 million, up from \$143.5 million at year-end 2025. Cash and cash equivalents stood at \$49.8 million.

Share Repurchase Program

• Buyback Activity: During Q1 2026, Viemed repurchased and cancelled 150,000 common shares at a total cost of \$1.4 million (excluding taxes), reflecting an average buyback price of \$9.29 per share. This activity demonstrates management’s confidence in the Company’s valuation and strategic use of capital to enhance shareholder value.

Operational & Strategic Updates

• Continued Growth: The Company continues to execute on its strategy to expand its respiratory care services and home medical equipment offerings, which has supported the double-digit revenue increase year-over-year.
• Conference Call: Viemed will host an investor conference call to discuss the results and provide 2026 guidance on Wednesday, May 6, 2026, at 11:00 a.m. ET. Details for dial-in and webcast are available on the Company’s website.

Shareholder and Price-Sensitive Information

• Strong Revenue Growth: The significant year-over-year revenue increase positions Viemed as a growth story in the healthcare sector, which may positively influence investor sentiment and share price.
• Share Repurchases: The buyback program signals management’s belief that shares are undervalued, which historically can support share price appreciation.
• Stable Profitability Amid Growth: Maintaining net income levels despite rising operating expenses and investments in the business demonstrates strong financial discipline.
• Liquidity and Capital Allocation: With over \$49 million in cash and ongoing free cash flow generation, Viemed is well-positioned to pursue further growth initiatives, potential acquisitions, or additional shareholder returns.
• Non-GAAP Guidance: The Company’s financial guidance for 2026, provided on a non-GAAP basis (e.g., Adjusted EBITDA, free cash flow), cannot be fully reconciled to GAAP due to the unpredictable nature of certain expenses and items, as disclosed in the forward-looking statements section.

Risks and Forward-Looking Statements

The Company notes that its forward-looking statements, including 2026 guidance, are subject to numerous risks and uncertainties such as economic conditions, regulatory changes, competitive pressures, and the unpredictable impacts of health events or technology disruptions. Investors are encouraged to review the risk factors detailed in Viemed’s filings with the SEC and Canadian securities regulators.

Conclusion

Viemed Healthcare’s Q1 2026 results underscore the Company’s solid growth trajectory, disciplined capital management, and ongoing commitment to delivering value to shareholders. The robust balance sheet, consistent profitability, and active share repurchase program are potential share price catalysts and warrant close attention from investors. The forthcoming conference call is expected to provide further insights into Viemed’s 2026 outlook and strategic priorities.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. Investors should review the full filings and consult financial advisors before making investment decisions.

View VIEMED HEALTHCARE, INC. Historical chart here